A Periodical for the Sarcoma Community

August 2005 - Volume 2, Number 4

Reflections on the Bayeux Tapestry

Editorial by Bruce Shriver, PhD

AP23573: A Review of Recent Results

Drs. Chawla, Sankhala, Mita, and Tolcher discuss AP23573, an mTOR inhibitor, which was granted fast-track designation by the FDA for patients with soft tissue and bone sarcomas. It is a unique and promising agent for treating sarcoma.

Clear Cell Sarcoma and Alveolar Soft Part Sarcoma

Drs. Goldberg and Albritton discuss two very rare soft tissue sarcomas, clear cell sarcoma and alveolar soft part sarcoma. They explore why some investigators propose that they may have a molecular similarity that could serve as a target for treatment using a vaccine.

Have We Made Any Progress?

Dr. Murray F. Brennan, who recently received the Nobility in Science award from the Sarcoma Foundation of America, shares with us some of his insights about the progress that has been made in dealing with sarcoma over the last 30-years.